Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice

Neurobiology of Disease

Volumn 17, Issue 2, 2004, Pages 319-325

  Norflus, Fran ^a   Nanje, Agnes ^b   Gutekunst, Claire Anne ^b   Shi, Geming ^b   Cohen, Joshua ^a   Bejarano, Michelle ^a   Fox, Jonathan ^a   Ferrante, Robert J ^c,d   Hersch, Steven M ^a,e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MassGeneral Inst for Neurodeg Dis   (United States)

Author keywords

Acetylsalicylate; Anti inflammatory; COX2 inhibition; Huntington's disease; Neurodegeneration; Rofecoxib; Therapeutics

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; ROFECOXIB;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; HUNTINGTON CHOREA; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; WEANING; WEIGHT REDUCTION;

ACOUSTIC STIMULATION; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BODY WEIGHT; CORPUS STRIATUM; CYCLOOXYGENASE INHIBITORS; HUNTINGTON DISEASE; LACTONES; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURAL INHIBITION; NEUROPROTECTIVE AGENTS; PROSENCEPHALON; STARTLE REACTION; SULFONES;

EID: 5144223534     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.07.011     Document Type: Article

References (34)

1. G. Almer, C. Guegan, P. Teismann, A. Naini, G. Rosoklija, A.P. Hays, C. Chen, and S. Przedborski Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis Ann. Neurol. 49 2 2001 176 185
2. O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, B.G. Jenkins, K.L. Ferrante, M. Thomas, A. Friedlich, S.E. Browne, G. Schilling, D.R. Borchelt, S.M. Hersch, C.A. Ross, and M.F. Beal Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease Neurobiol. Dis. 8 3 2001 479 491
3. P. Barneoud, and O. Curet Beneficial effects of lysine acetylsalicylate, a soluble salt of aspirin on motor performance in a transgenic model of amyotrophic lateral sclerosis Exp. Neurol. 155 1999 243 251
4. J. Carmichael, J. Chatellier, A. Woolfson, C. Milstein, A.R. Fersht, and D.C. Rubinsztein Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 97 17 2000 9701 9705
5. R.J. Carter, L.A. Lione, T. Humbly, L. Mangioarini, A. Mahal, G.P. Bates, S.B. Dunnett, and A.J. Morton Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation J. Neurosci. 19 8 1999 3248 3257
6. H.Y. Chan, J.M. Warrick, G.L. Gray-Board, H.L. Paulson, and N.M. Bonini Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila Hum. Mol. Genet. 9 19 2000 2811 2820
7. M. Chen, V.O. Ona, M. Li, R.J. Ferrante, K.B. Fink, S. Zhu, L. Guo, L.A. Farrell, S.M. Hersch, W. Hobbs, J.P. Vonsattel, J.J. Cha, and R.M. Friedlander Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington's disease Nat. Med. 6 7 2000 797 801
8. J.Z. Chuang, H. Zhou, M. Zhu, S.H. Li, X.J. Li, and C.H. Sung Characterization of a brain-enriched chaperone, MRJ, that inhibits huntingtin aggregation and toxicity independently J. Biol. Chem. 277 22 2002 19831 19838
9. J.D. Cristobal, A. Cardenas, I. Lizasoain, J.C. Leza, P. Fernandez-Tome, P. Lorenzo, and M.A. Moro Inhibition of glutamate release via recovery of ATP levels accounts or a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation Stroke 33 2002 261 267
10. A. Dedeoglu, J.K. Kubilus, T.M. Jeitner, S.A. Matson, M. Bogdanov, N.W. Kowall, W.R. Matson, A.J. Cooper, R.R. Ratan, M.F. Beal, S.M. Hersch, and R.J. Ferrante Therapeutic effects of cystamine in a murine model of Huntington's disease J. Neurosci. 22 20 2002 8942 8950
11. R.J. Ferrante, O.A. Andreassen, B.G. Jenkins, A. Dedeoglu, S. Kuemmerle, J.K. Kubilus, R. Kaddurah-Daouk, S.M. Hersch, and M.F. Beal Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease J. Neurosci. 20 12 2000 4389 4397
12. R.J. Ferrante, O.A. Andreassen, A. Dedeoglu, K.L. Ferrante, B.G. Jenkins, S.M. Hersch, and M.F. Beal Therapeutic effects of coenzyme Q10 and remacimide in transgenic mouse models of Huntington's disease J. Neurosci. 22 5 2002 1592 1599
13. R.J. Ferrante, J.K. Kubilus, J. Lee, H. Ryu, A. Beesen, B. Zucker, K. Smith, N.W. Kowall, R.R. Ratan, R. Luthi-Carter, and S.M. Hersch Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice J. Neurosci. 232 28 2003 9418 9427
14. M. Grilli, M. Pizzi, M. Memo, and P. Spano Neuroprotection by aspirin and sodium salicylate through blockage of NF-κB activation Science 274 1996 1383 1385
15. J.L. Hillson, and D.E. Furst Rofecoxib Expert Opin. Pharmacother. 1 5 2000 1053 1066
16. E. Hockly, V.M. Richon, B. Woodman, D.L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P.A. Lowden, J.S. Steffan, J.L. Marsh, L.M. Thompson, C.M. Lewis, P.A. Marks, and G.P. Bates Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proc. Natl. Acad. Sci. U. S. A. 100 4 2003 2041 2046
17. N.R. Jana, M. Tanaka, G. Wang, and N. Nukina Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity Hum. Mol. Genet. 9 13 2000 2009 2018
18. M.V. Karpuj, M.W. Becher, J.E. Springer, D. Chabas, S. Youssef, R. Pedotti, D. Mitchell, and L. Steinman Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine Nat. Med. 8 2 2002 143 149
19. Davies G. Kleinbaum The Cox proportional hazards model and its characteristics K. Dietz K. Krickeberg M. Gail B. Singer Survival analysis: a self-learning text 1996 Springer New York 83 111
20. P. Klivenyi, M. Kiaei, G. Gardian, N.Y. Calingasan, and M.F. Beal Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic model of amyotrophic lateral sclerosis J. Neurorchem. 88 2004 576 582
21. S. Krobitsch, and S. Lindquist Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins Proc. Natl. Acad. Sci. U. S. A. 97 4 2000 1589 1594
22. T. Kunz, and E.H. Oliw The selective cyclooxygenase-2 inhibitor rofecoxib reduces kainite-induced cell death in the rat hippocampus Eur. J. Neurosci. 13 3 2001 569 575
23. G.P. Lim, F. Yang, T. Chu, P. Chen, W. Beech, B. Teter, T. Tran, O. Ubeda, K.H. Ashe, S.A. Frautschy, and G.M. Cole Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease J. Neurosci. 20 15 2000 5709 5714
24. L. Mangiarini, K. Sathasivam, M. Seller, B. Cozens, A. Harper, C. Hetherington, M. Lawton, Y. Trottier, H. Lehrach, S.W. Davies, and G.P. Bates Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurologic phenotype in transgenic mice Cell 87 1996 493 506
25. J.K. Ryu, A. Nagai, J. Kim, M.C. Lee, J.G. McLarnon, and S.U. Kim Microglial activation and cell death induced by the mitochondrial toxin 3-nitropropionic acid: in vitro and in vivo studies Neurobiol. Dis. 12 2003 121 132
26. E. Sapp, K.B. Kegel, N. Aronin, T. Hashikawa, Y. Uchiyama, K. Tohyama, P.G. Bhide, J.P. Vonsattel, and M. DiFiglia Early and progressive accumulation of reactive microglia in the Huntington disease brain J. Neuropathol. Exp. Neurol. 60 2 2001 161 172
27. G. Schilling, M.W. Becher, A.H. Sharp, H.A. Jinnah, K. Duan, J.A. Kotzuk, H.H. Slunt, T. Ratovitski, J.K. Cooper, N.A. Jenkins, N.G. Copeland, D.L. Price, C.A. Ross, and D.R. Borchelt Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin Hum. Mol. Genet. 8 3 1999 397 407
28. G. Schilling, A.V. Savonenko, M.L. Coonfield, J.L. Morton, E. Vorovich, A. Gale, C. Neslon, N. Chan, M. Eaton, D. Fromholt, C.A. Ross, and D.R. Borchelt Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice Exp. Neurol. 60 2 2004 161 172
29. J.S. Steffan, L. Bodai, J. Pallos, M. Poelman, A. McCampbell, B.L. Apostol, A. Kazanstev, E. Schmidt, Y.Z. Zhu, M. Greenwald, R. Kurokawa, D.E. Housman, G.R. Jackson, J.L. Marsh, and L.M. Thompson Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila Nature 413 2001 739 743
30. J.S. Sundy Cox-2 inhibitors in rheumatoid arthritis Curr. Rheumatol. Rep. 3 1 2001 86 91
31. M.S. Swamy, and E.C. Abraham Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo Invest. Opthalmol. Visn. Sci. 30 6 1989 1120 1126
32. N.R. Swerdlow, J. Paulsen, D.L. Braff, N. Butters, M.A. Greyer, and M.R. Swenson Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease J. Neurol. Neurosurg. Psychiatry 58 1995 192 200
33. A. Wyttenbach, O. Sauvageot, J. Carmichael, C. Diaz-Latoud, A.P. Arrigo, and D.C. Rubinszstein Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin Hum. Mol. Genet. 11 9 2002 1137 1151
34. M. Yao, S. Kargman, E.C. Lam, C.R. Kelley, Y. Zheng, P. Luk, E. Kwong, J.F. Evans, and M.M. Wolfe Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice Cancer Res. 63 2003 586 592